Chimerix Inc
CXF
Company Profile
Business description
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
Contact
2505 Meridian Parkway
Suite 100
DurhamNC27713
USAT: +1 919 806-1074
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
72
Stocks News & Analysis
stocks
The fight for Insignia continues
Numerous acquisition proposals vindicate Insignia's improved earnings momentum.
stocks
Trouble continues as Star Entertainment burns through cash
More pain in the horizon as the company struggles to stay afloat.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,652.70 | 58.30 | 0.68% |
| CAC 40 | 7,743.70 | 10.20 | 0.13% |
| DAX 40 | 20,977.49 | 12.82 | -0.06% |
| Dow JONES (US) | 43,487.83 | 334.70 | 0.78% |
| FTSE 100 | 8,523.49 | 2.95 | 0.03% |
| HKSE | 20,106.55 | 180.74 | 0.91% |
| NASDAQ | 19,630.20 | 291.91 | 1.51% |
| Nikkei 225 | 39,027.98 | 125.48 | 0.32% |
| NZX 50 Index | 13,052.90 | 35.41 | -0.27% |
| S&P 500 | 5,996.66 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,402.40 | 55.00 | 0.66% |
| SSE Composite Index | 3,242.62 | 1.76 | -0.05% |